Skip to main content
KAZIA THERAPEUTICS LTD logo

KAZIA THERAPEUTICS LTD — Investor Relations & Filings

Ticker · KZIA ISIN · US48669G1058 US Professional, scientific and technical activities
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2024-10-24 Capital/Financing Update
Country US United States of America
Listing US KZIA

About KAZIA THERAPEUTICS LTD

https://www.kaziatherapeutics.com/

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company engaged in the development of innovative drugs for cancer. The company's lead program is paxalisib, a small molecule inhibitor of the PI3K/AKT/mTOR pathway designed to cross the blood-brain barrier, which is being investigated for various forms of brain cancer. Its development pipeline also includes EVT801, a selective VEGFR3 inhibitor being studied for its potential to block the growth of blood and lymphatic vessels that support tumor growth. The company focuses on addressing cancers with high unmet medical needs through its portfolio of targeted therapies.

Recent filings

Filing Released Lang Actions
424B3
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K/A filed pursuant to Rule 424(b)(3) and is a prospectus supplement updating a previously filed prospectus. It discusses an amendment to a Form 6-K report related to a change in the ADS ratio (American Depositary Shares to Ordinary Shares). The document is relatively short (4318 characters) and primarily serves to update and clarify information about a share ratio change. It does not contain comprehensive financial statements or detailed financial analysis. The document is essentially an announcement and update related to capital structure changes and prospectus information. Given the nature of the content—updating a prospectus and announcing a change in ADS ratio—it fits best under Capital/Financing Update (CAP).
2024-10-24 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 6-K/A filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, which is an amendment to a previously filed Form 6-K. It updates information about a change in the ratio of American Depositary Shares to Ordinary Shares, clarifying the effect of the ADS ratio change. The document does not contain financial statements or detailed financial analysis but is an update to a regulatory filing. It is not a full report like an Annual Report (10-K) or Interim Report (IR), nor is it a prospectus or capital raising announcement. Given the nature of the filing as an amendment to a Form 6-K and the absence of substantive financial data, this fits best under Regulatory Filings (RNS). The document length is 4324 characters, which is relatively short and consistent with a regulatory filing update rather than a full report.
2024-10-24 English
6-K/A
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K/A filed with the SEC by a foreign private issuer, Kazia Therapeutics Limited. It is an amendment to a previously filed Form 6-K report. The content clarifies a change in the ADS ratio, which is related to capital structure but does not itself constitute a full financial report or detailed financial data. The document is short (2118 characters) and serves as an update or clarification rather than a full report. It is not an earnings release, annual report, or interim report. It is also not a proxy, voting result, or management change announcement. The nature of the amendment relates to capital structure (ADS ratio change), which fits best under Capital/Financing Update (CAP). Given the document's content and length, the classification as CAP is appropriate with high confidence.
2024-10-24 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by Kazia Therapeutics Limited, which is a report of a foreign private issuer pursuant to SEC rules. It announces a change in the ratio of American Depositary Shares (ADS) to Ordinary Shares, explaining the details and implications of this change. The document is not a full financial report, earnings release, or management discussion, but rather an update on a capital structure change related to ADS ratio adjustment. It is not a report publication announcement or a certification. The key content is about a capital structure update affecting the company's securities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (7195 characters) supports it being a substantive filing rather than a brief announcement. Confidence is high given the clear focus on capital structure change and the nature of Form 6-K filings for such updates.
2024-10-15 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by Kazia Therapeutics Limited, which is a report of a foreign private issuer pursuant to SEC rules. It announces a change in the ratio of American Depositary Shares (ADS) to Ordinary Shares, explaining the details and implications of this change. The document is a regulatory filing providing an update on capital structure related to ADS ratio change but does not contain financial statements or detailed financial analysis. It is not a full financial report, earnings release, or investor presentation. The document is not a report publication announcement since it contains substantive information about the ADS ratio change. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-10-15 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by Kazia Therapeutics Limited, which is a report of a foreign private issuer pursuant to SEC rules. It announces a change in the ratio of American Depositary Shares (ADS) to Ordinary Shares, which is a capital structure update. The document is not a full financial report, earnings release, or management discussion, but rather an update on a specific corporate action related to share structure. It is not a report publication announcement or a certification. The key content is about the ADS ratio change to regain compliance with Nasdaq listing rules, which fits the category of Capital/Financing Update (CAP). The document length is 7201 characters, which is substantive and contains detailed information about the capital change. Therefore, the appropriate classification is CAP with high confidence.
2024-10-15 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.